Pilot randomized controlled trial evaluating the effect of hypertonic saline with and without hyaluronic acid in reducing inflammation in cystic fibrosis

Anna Brivio, Massimo Conese, Simone Gambazza, Arianna Biffi, Amedea Silvia Tirelli, Maria Russo, Michaela Foà, Carla Colombo

Research output: Contribution to journalArticle

Abstract

Background: Hypertonic saline (HS) has been established as a therapy aimed at restoring the surface liquid of airways liquid and enhancing mucociliary clearance in patients with cystic fibrosis (CF). A formula containing 7% HS and 0.1% hyaluronic acid (HA) is also available, basing its use on the protective effects of HA against elastin injury and on its greater ease of administration (i.e., the perceived acceptability of inhalation). This study explores the effect of HA+HS in reducing the inflammation of airways, by measuring cytokine levels in sputum, its safety profile, and the prevalence of commonly reported symptoms like cough, throat irritation, and saltiness. Methods: In a pilot, double-blind, randomized controlled, parallel-group, 1:1 trial, clinically stable CF patients older than 6 years of age and with a FEV 1 pred. >40% were randomized to one of the treatment arms, HS or HS+HA, to be administered twice a day at home. Clinical data, inflammatory markers (IL-1β, IL-6, IL-8, IL-10, TNF-α, VEGF) in sputum, and judgments on the tolerability and pleasantness were collected at the beginning and after 28 days. Results: HA+HS had no significant effect on inflammatory markers versus HS alone, as shown by broad confidence intervals. In the HS+HA group, the highest decrement from baseline values was observed for IL-1β (â '58.8%) followed by VEGF (â '49.9%), whereas in the HS group a significant increment of IL-10 levels (+83.0%; p = 0.011) was the only significant finding. Prevalence of unfavorable scores was 36.8% in HA+HS versus 55% in HS group (p = 0.207); no significant differences were detected in the prevalence of moderate/severe symptoms of cough, saltiness, and throat irritation in pulmonary functions tests after 28 days. Conclusions: HS+HA administration in CF patients does not show any significant effects on lung inflammation and function as compared to HS alone.

Original languageEnglish
Pages (from-to)482-489
Number of pages8
JournalJournal of Aerosol Medicine and Pulmonary Drug Delivery
Volume29
Issue number6
DOIs
Publication statusPublished - Dec 1 2016

    Fingerprint

Keywords

  • Clinical trial
  • Cystic fibrosis
  • Cytokines
  • Hyaluronic acid
  • Hypertonic saline
  • Lung function

ASJC Scopus subject areas

  • Medicine(all)
  • Pulmonary and Respiratory Medicine
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this